Highlights from American Diabetes Association meeting

27 June 2011

There was a batch of good news coming out of the American Diabetes Association (ADA) 71st annual scientific meeting taking place over the weekend in San Diego, California. This including positive results for type 2 diabetes products from Novo Nordisk, AstraZeneca, Bristol-Myers Squibb and Sanofi.

Victoza patients saw significant weight loss

Denmark’s Novo Nordisk (NVO: N) presented data which show that Victoza (liraglutide [rDNA origin] injection), taken once daily, in combination with metformin and/or sulfonylurea, helped more patients achieve blood sugar control when compared with other commonly used type 2 diabetes therapies. Although not a weight loss product, the data also demonstrate that patients experienced significant weight loss when switched from sitagliptin to Victoza.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK